Novel respiratory infectious diseases in Korea

키워드

참고문헌 (97)

1. Johnson NP, "Updating the accounts : global mortality of the 1918-1920"Spanish"influenza pandemic", Bull Hist Med, 76, pp.105~115 (2002)
2. Guarner J, "Three emerging coronaviruses in two decades", Am J Clin Pathol, 153, pp.420~421 (2020)
3. Dowell SF, "Seasonality of infectious diseases and severe acute respiratory syndrome-what we don’t know can hurt us", Lancet Infect Dis, 4, pp.704~708 (2004)
4. Nicholson KG, "Influenza", Lancet, 362, pp.1733~1745 (2003)
5. Ghendon Y, "Introduction to pandemic influenza through history", Eur J Epidemiol, 10, pp.451~453 (1994)
6. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, "Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection", N Engl J Med, 362, pp.1708~1719 (2010)
7. Lessler J, "Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school", N Engl J Med, 361, pp.2628~2636 (2009)
8. 홍관, "Estimating Influenza-associated Mortality in Korea: The 2009-2016 Seasons", 예방의학회지, 52(5), pp.308~315 (2019), 대한예방의학회[DOI]
9. Paules C, "Influenza", Lancet, 390, pp.697~708 (2017)
10. Zangrillo A, "Extracorporeal membrane oxygenation(ECMO)in patients with H1N1 influenza infection : a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO", Crit Care, 17, pp.R30~ (2013)
11. Noah MA, "Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)", JAMA, 306, pp.1659~1668 (2011)
12. 조재화, "중환자실 구성이 2009년 인플루엔자 A", H1N1 중증환자의 사망률에 미친 영향, 2012, pp.27(2), 65~69[DOI]
13. Dwyer DE, "Laboratory diagnosis of human seasonal and pandemic influenza virus infection", Med J Aust, 185, pp.S48~S53 (2006)
14. Peaper DR, "Rapid diagnosis of influenza : state of the art", Clin Lab Med, 34, pp.365~385 (2014)
15. Uyeki TM, "Clinical practice guidelines by the Infectious Diseases Society of America : 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa", Clin Infect Dis, 68, pp.e1~e47 (2019)
16. Hayden FG, "Baloxavir marboxil for uncomplicated influenza in adults and adolescents", N Engl J Med, 379, pp.913~923 (2018)
17. Hirotsu N, "Baloxavir marboxil in Japanese pediatric patients with influenza : safety and clinical and virologic outcomes", Clin Infect Dis, 71, pp.971~981 (2020)
18. Ison MG, "Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial", Lancet Infect Dis, 20, pp.1204~1214 (2020)
19. The Lancet, "Preparing for seasonal influenza", Lancet, 391, pp.180~ (2018)
20. Hayden FG, "Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis", J Infect Dis, 189, pp.440~449 (2004)
21. Hayden FG, "Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group", N Engl J Med, 343, pp.1282~1289 (2000)
22. Uyeki TM, "Baloxavir for postexposure prophylaxis against influenza in households", N Engl J Med, 383, pp.389~390 (2020)
23. Hak E, "Influenza vaccinations: who needs them and when?", Drugs, 62, pp.2413~2420 (2002)
24. Peiris JS, "Coronavirus as a possible cause of severe acute respiratory syndrome", Lancet, 361, pp.1319~1325 (2003)
25. Ksiazek TG, "A novel coronavirus associated with severe acute respiratory syndrome", N Engl J Med, 348, pp.1953~1966 (2003)
26. Drosten C, "Identification of a novel coronavirus in patients with severe acute respiratory syndrome", N Engl J Med, 348, pp.1967~1976 (2003)
27. Gu J, "Pathology and pathogenesis of severe acute respiratory syndrome", Am J Pathol, 170, pp.1136~1147 (2007)
28. Marra MA, "The genome sequence of the SARS-associated coronavirus", Science, 300, pp.1399~1404 (2003)
29. 임수, "한국에서 경험한 유입된 중증 급성호흡기증후군 추정 환자 3예", 대한내과학회지, 67(6), pp.655~661 (2004), 대한내과학회
30. de Wit E, "SARS and MERS : recent insights into emerging coronaviruses", Nat Rev Microbiol, 14, pp.523~534 (2016)
31. Liu CL, "Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever", Chest, 126, pp.509~517 (2004)
32. Cheng VC, "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection", Clin Microbiol Rev, 20, pp.660~694 (2007)
33. Tsang KW, "A cluster of cases of severe acute respiratory syndrome in Hong Kong", N Engl J Med, 348, pp.1977~1985 (2003)
34. Rota PA, "Characterization of a novel coronavirus associated with severe acute respiratory syndrome", Science, 300, pp.1394~1399 (2003)
35. Wong KT, "Severe acute respiratory syndrome : radiographic appearances and pattern of progression in 138 patients", Radiology, 228, pp.401~406 (2003)
36. Lee N, "A major outbreak of severe acute respiratory syndrome in Hong Kong", N Engl J Med, 348, pp.1986~1994 (2003)
37. Hui DS, "SARS : clinical features and diagnosis", Respirology, 8(Suppl 1), pp.S20~S24 (2003)
38. Chan PK, "Laboratory diagnosis of SARS", Emerg Infect Dis, 10, pp.825~831 (2004)
39. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
40. Seto WH, "Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome(SARS)", Lancet, 361, pp.1519~1520 (2003)
41. Zaki AM, "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N Engl J Med, 367, pp.1814~1820 (2012)
42. Hui DS, "Middle East respiratory syndrome coronavirus : risk factors and determinants of primary, household, and nosocomial transmission", Lancet Infect Dis, 18, pp.e217~e227 (2018)
43. Kim KH, "Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications", J Hosp Infect, 95, pp.207~213 (2017)
44. Memish ZA, "Middle East respiratory syndrome", Lancet, 395, pp.1063~1077 (2020)
45. Assiri A, "Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study", Lancet Infect Dis, 13, pp.752~761 (2013)
46. Arabi YM, "Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection", Ann Intern Med, 160, pp.389~397 (2014)
47. 최원진, "Middle East Respiratory Syndrome-Coronavirus Infection: A Case Report of Serial Computed Tomographic Findings in a Young Male Patient", Korean Journal of Radiology, 17(1), pp.166~170 (2016), 대한영상의학회[DOI]
48. Ajlan AM, "Middle East respiratory syndrome coronavirus(MERS-CoV)infection : chest CT findings", AJR Am J Roentgenol, 203, pp.782~787 (2014)
49. Elkholy AA, "MERS-CoV infection among healthcare workers and risk factors for death : retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018", J Infect Public Health, 13, pp.418~422 (2020)
50. World Health Organization, "Laboratory biorisk management for laboratories handling human specimens suspected or confirmed to contain influenza A (H1N1) causing the current international epidemics", World Health Organization, ~ (2009)
51. Huang P, "A rapid and specific assay for the detection of MERS-CoV", Front Microbiol, 9, pp.1101~ (2018)
52. "Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: interim guidance" (2019)[URL]
53. 정용필, "Antiviral Treatment Guidelines for Middle East Respiratory Syndrome", Infection and Chemotherapy, 47(3), pp.212~222 (2015), 대한감염학회
54. Mo Y, "A review of treatment modalities for Middle East Respiratory Syndrome", J Antimicrob Chemother, 71, pp.3340~3350 (2016)
55. Baharoon S, "MERS-CoV as an emerging respiratory illness : a review of prevention methods", Travel Med Infect Dis, 32, pp.101520~ (2019)
56. Petrosillo N, "COVID-19, SARS and MERS: are they closely related?", Clin Microbiol Infect, 26, pp.729~734 (2020)
57. Jin Y, "Virology, epidemiology, pathogenesis, and control of COVID-19", Viruses, 12, pp.372~ (2020)
58. Rabaan AA, "SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview", Infez Med, 28, pp.174~184 (2020)
59. "Coronavirus disease (COVID-19): situation report, 176" (2020)[URL]
60. Bourouiba L, "Turbulent gas clouds and respiratory pathogen emissions : potential implications for reducing transmission of COVID-19", JAMA, 323, pp.1837~1838 (2020)
61. Lewis D, "Is the coronavirus airborne? Experts can’t agree", Nature, 580, pp.175~ (2020)
62. Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", N Engl J Med, 382, pp.970~971 (2020)
63. Goyal P, "Clinical characteristics of Covid-19 in New York City", N Engl J Med, 382, pp.2372~2374 (2020)
64. Baj J, "COVID-19 : specific and non-specific clinical manifestations and symptoms : the current state of knowledge", J Clin Med, 9, pp.1753~ (2020)
65. Yonghyun Lee, "Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients", Journal of Korean Medical Science, 35(18), pp.1~6 (2020), 대한의학회[DOI]
66. Zhang Y, "Coagulopathy and antiphospholipid antibodies in patients with Covid-19", N Engl J Med, 382, pp.e38~ (2020)
67. 김동욱, "The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data", Journal of Korean Medical Science, 35(26), pp.1~9 (2020), 대한의학회[DOI]
68. Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review", JAMA, 324, pp.782~783 (2020)
69. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
70. Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
71. Ki Tae Kwon, "Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak", Journal of Korean Medical Science, 35(11), pp.1~4 (2020), 대한의학회[DOI]
72. Mulangu S, "A randomized, controlled trial of Ebola virus disease therapeutics", N Engl J Med, 381, pp.2293~2303 (2019)
73. Holshue ML, "First case of 2019 novel coronavirus in the United States", N Engl J Med, 382, pp.929~936 (2020)
74. John H. Beigel, "Remdesivir for the Treatment of Covid-19 — Final Report", New England Journal of Medicine, 383(19), pp.1813~1826 (2020), Massachusetts Medical Society[DOI]
75. Jason D. Goldman, "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19", New England Journal of Medicine, 383(19), pp.1827~1837 (2020), Massachusetts Medical Society[DOI]
76. Grein J, "Compassionate use of remdesivir for patients with severe Covid-19", N Engl J Med, 382, pp.2327~2336 (2020)
77. Lee Choongman, "Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series", Infection and Chemotherapy, 52(3), pp.369~380 (2020), 대한감염학회[DOI]
78. Norrie JD, "Remdesivir for COVID-19 : challenges of underpowered studies", Lancet, 395, pp.1525~1527 (2020)
79. Devaux CA, "New insights on the antiviral effects of chloroquine against coronavirus : what to expect for COVID-19", Int J Antimicrob Agents, 55, pp.105938~ (2020)
80. Alexandre B. Cavalcanti, "Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19", New England Journal of Medicine, 383(21), pp.2041~2052 (2020), Massachusetts Medical Society[DOI]
81. Hong Kyung Soo, "Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication", Infection and Chemotherapy, 52(3), pp.396~402 (2020), 대한감염학회[DOI]
82. Lim J, "Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea : the application of lopinavir", ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, 2020, pp.35, e79~
83. Ji-Won Kim, "Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019", The Korean Journal of Internal Medicine, 36, pp.253~263 (2021), 대한내과학회[DOI]
84. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
85. Zhang JJ, "Risk factors of severe dsease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis", Clin Infect Dis (2020)[DOI]
86. Cheng CY, "Lopinavir", ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan, 2020, pp.53, 488~492
87. Garraud O, "Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow", Transfus Clin Biol, 23, pp.39~44 (2016)
88. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
89. Yeh KM, "Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital", J Antimicrob Chemother, 56, pp.919~922 (2005)
90. Bloch EM, "Deployment of convalescent plasma for the prevention and treatment of COVID-19", J Clin Invest, 130, pp.2757~2765 (2020)
91. Li L, "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19 : a randomized clinical trial", JAMA, 324, pp.1~11 (2020)
92. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
93. RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with covid-19–preliminary report", New England Journal of Medicine (2020), Massachusetts Medical Society[DOI]
94. Huet T, "Anakinra for severe forms of COVID-19 : a cohort study", Lancet Rheumatol, 2, pp.e393~e400 (2020)
95. Thanh Le T, "The COVID-19 vaccine development landscape", Nat Rev Drug Discov, 19, pp.305~306 (2020)
96. Lurie N, "Developing Covid-19 vaccines at pandemic speed", N Engl J Med, 382, pp.1969~1973 (2020)
97. Chu DK, "Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis", Lancet, 395, pp.1973~1987 (2020)

관련 논문AI추천